Posted On: 03/18/2014 11:34:21 AM
Post# of 63824
$PVCT higher lows after correction $2.15
from 9/19/13 flag $0.80
Shares Outstanding 145,723,430 a/o Nov 08, 2013
Float 95,000,000 a/o Jul 15, 2013
Authorized Shares 250,000,000 a/o Jul 15, 2013
Par Value 0.001
PV-10 Immune Mechanism Data to Be Presented at the American Association for Cancer Research Annual Meeting
3/6/2014 11:58:00 AM - Business Wire
Provectus Announces PV-10’s Assessment for Drug-Drug Interaction Potential is Subject of Article Published by Xenobiotica
1/28/2014 12:52:00 PM - Business Wire
Provectus's PV-10 Path to Initial Approval in U.S. Now Clear Per FDA Meeting Minutes
1/24/2014 12:09:00 PM - Business Wire
Provectus Type C Meeting With FDA Oncology Division Held December 16, 2013
12/18/2013 7:10:00 AM - Business Wire
Provectus Announces Name Change to Provectus Biopharmaceuticals, Inc. and Reincorporates in Delaware
12/17/2013 6:00:00 AM - Business Wire
from 9/19/13 flag $0.80
Shares Outstanding 145,723,430 a/o Nov 08, 2013
Float 95,000,000 a/o Jul 15, 2013
Authorized Shares 250,000,000 a/o Jul 15, 2013
Par Value 0.001
PV-10 Immune Mechanism Data to Be Presented at the American Association for Cancer Research Annual Meeting
3/6/2014 11:58:00 AM - Business Wire
Provectus Announces PV-10’s Assessment for Drug-Drug Interaction Potential is Subject of Article Published by Xenobiotica
1/28/2014 12:52:00 PM - Business Wire
Provectus's PV-10 Path to Initial Approval in U.S. Now Clear Per FDA Meeting Minutes
1/24/2014 12:09:00 PM - Business Wire
Provectus Type C Meeting With FDA Oncology Division Held December 16, 2013
12/18/2013 7:10:00 AM - Business Wire
Provectus Announces Name Change to Provectus Biopharmaceuticals, Inc. and Reincorporates in Delaware
12/17/2013 6:00:00 AM - Business Wire
(0)
(0)
